Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Risperidone ISM® Effectiveness in Schizophrenia Patients Hospitalised Due to A Relapse: a Prospective Non-interventional Evaluation (RESHAPE Study)

NCT05480046 is registered in ClinicalTrials.gov with Rovi Pharmaceuticals Laboratories as lead sponsor.

NCT NCT05480046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05480046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Risperidone ISM® Effectiveness in Schizophrenia Patients Hospitalised Due to A Relapse: a Prospective Non-interventional Evaluation (RESHAPE Study)
Lead sponsor
Rovi Pharmaceuticals Laboratories
Phase
Observational
Overall status
Completed
Start date
October 18, 2022
Completion date
March 13, 2025
Enrollment
275 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia